康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09926 康方生物

已收盘 05-27 16:09:08

115.200

+3.000

+2.67%

最高116.200	最低110.600	成交量643.78万
今开113.300	昨收112.200	日振幅4.99%
总市值1,061亿	流通市值1,061亿	总股本9.21亿
成交额7.39亿	换手率0.70%	流通股本9.21亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"康方生物","latestPrice":115.2,"timestamp":1779869348010,"preClose":112.2,"halted":0,"volume":6437762,"delay":0,"changeRate":0.026737967914438502,"floatShares":921000000,"shares":921000000,"eps":-1.232771,"marketStatus":"已收盘","change":3,"latestTime":"05-27 16:09:08","open":113.3,"high":116.2,"low":110.6,"amount":738847158,"amplitude":0.049911,"askPrice":115.2,"askSize":5000,"bidPrice":114.8,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-1.37184,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779931800000},"marketStatusCode":5,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":112.2,"openAndCloseTimeList":[[1779845400000,1779854400000],[1779858000000,1779868800000]],"volumeRatio":0.83299,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.7303,"impliedVolPercentile":0.9529},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"1143373936","title":"异动解读｜康方生物盘中上涨3.03%，ASCO全体大会口头报告临近催化市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1143373936","media":"行情直击","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143373936?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:09","pubTimestamp":1779851383,"startTime":"0","endTime":"0","summary":"5月27日，康方生物盘中上涨3.03%，报115.6港元/股，成交额2.59亿港元。消息面上，ASCO年会将于5月29日开幕，康方生物核心产品依沃西单抗HARMONi-6研究入选全体大会口头报告，将公布总生存期数据，这是历史上首个来自中国的First-in-Class新药入选ASCO全体大会环节，市场对即将揭晓的关键生存数据寄予期待。同日生物科技板块多数个股表现偏弱，康方生物逆势上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178608706","title":"异动解读｜康方生物盘中下跌3.09%，依沃西单抗全球三期中期未达终点持续压制估值","url":"https://stock-news.laohu8.com/highlight/detail?id=1178608706","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178608706?lang=zh_cn&edition=full","pubTime":"2026-05-26 09:56","pubTimestamp":1779760615,"startTime":"0","endTime":"0","summary":"5月26日，康方生物盘中下跌3.09%，报113.6港元/股，成交额2.74亿港元。市场仍在持续消化其核心产品依沃西单抗全球关键三期HARMONi-3研究中期分析不及预期的影响。尽管此前ASCO摘要解禁及卡度尼利单抗新适应症获批临床等利好一度推动股价反弹，但短期估值修复动能仍显不足，公司股价自前期高点已累计回调超25%。同日生物科技板块整体偏弱，三生制药跌3.9%、荣昌生物跌2.59%，康方生物跌幅居板块前列。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638534935","title":"格隆汇个股放量排行榜 | 5月25日","url":"https://stock-news.laohu8.com/highlight/detail?id=2638534935","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638534935?lang=zh_cn&edition=full","pubTime":"2026-05-25 17:30","pubTimestamp":1779701404,"startTime":"0","endTime":"0","summary":"股票名称成交额（万）量比持续放量天数天利控股集团26177.222.493百富环球2703.382.425中联发展控股1067.482.361优必选217973.061.981华润医疗1719.231.911滔搏3529.591.832胜宏科技350159.461.791数码通电讯961.431.781九龙仓集团17387.851.641蔚来-SW46990.051.551高鑫零售1589.461.521科伦博泰生物60133.001.496九福来102.461.451中集集团7903.471.441北大青鸟环宇360.511.371PACIFIC LEGEND740.851.361中海油田服务9347.601.361MOS HOUSE695.301.331百果园集团641.011.291中芯国际1651388.781.282量化派3423.981.231佰泽医疗5107.781.191时代天使8886.501.192五一视界215348.591.182稀美资源-五百6200.381.1710电讯盈科6323.451.171美格智能7545.751.171深圳高速公路股份1185.201.172森松国际19247.321.143兖矿能源47039.851.111大象未来集团855.821.091通通AI社交2016.021.061兆易创新243","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/25173057187788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01919","02259","02155","00117","09866","06990","02050","02172","00177","06110","00004","00384","02598","00165","00107","02685","03888","06613","01592","01473","02609","06681","02714","09880","02291","00081","01672","00981","00008","02565","06699","09993","00909","01211","02506","00087","02587","09626","01477","01516","06603","02418","09869","09926","08547","00152","02142","06955","00199","03986"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2638585985","title":"中金：恒指季检调整后工业与医疗保健业覆盖度提升，6只股票或纳入港股通","url":"https://stock-news.laohu8.com/highlight/detail?id=2638585985","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638585985?lang=zh_cn&edition=full","pubTime":"2026-05-25 13:59","pubTimestamp":1779688785,"startTime":"0","endTime":"0","summary":"参照恒指公司的行业分类，此次恒指调整后，对于医疗保健业的覆盖度从38.8%提升至44.3%，对于工业的覆盖度从54.3%提升至56.0%。该行根据此次恒生综合指数调整情况、结合港股通纳入的额外要求，预计6只或符合港股通纳入范围。此次进入恒生综合指数的Minimax-W由于其同股不同权性质，需额外满足上市满6个月及20个交易日的条件，因此不会在本次6月调整中进入港股通，预计于8月纳入港股通。若后续满足市值与成交额要求，有望于8月纳入港股通。","market":"us","thumbnail":"https://static.tigerbbs.com/38508134c6853c521e764dc952e7334a","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/38508134c6853c521e764dc952e7334a"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7ab48a17674d5845193952fa54058c28","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445467.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03417","07588","LU1719994722.HKD","HSI","LU0348766576.USD","03419","LU0348783233.USD","BK1568","83115","07200","03088","82800","07226","ONC","HSCEI","82828","BK1117","LU1961090484.USD","IE00B543WZ88.USD","BK1592","03416","LU0348825331.USD","00100","03032","BK1191","06160","02828","07288","07300","IE00B5MMRT66.SGD","LU0348735423.USD","IE00BPRC5H50.USD","LU1808992512.USD","BK1589","BK1500","02513","09067","LU0634319403.HKD","LU0588546209.SGD","BK1161","HK0000286598.CNH","LU2778985437.USD","LU1770034418.SGD","LU0348827113.USD","LU1251922891.USD","BK1513","LU2488822045.USD","LU1720050803.USD","LU1969619763.USD","03692","MCHmain","09115","01519","03067","LU0417516902.SGD","LU0307460666.USD","02837","03033","07552","BK1151","HSCI","HHImain","03115","LU0417516571.SGD","601600","LU1794554557.SGD","07500","02833","BK1583","LU0561508036.HKD","09088","09926","03423","LU1303224171.USD","LU0417516738.SGD","LU0348784397.USD","02800","LU2476274308.USD","513600","BK1588","LU2476274720.SGD","HSTECH","BK1574","LU2399975544.HKD","LU0540923850.HKD","BK1175","LU2328871848.SGD","03037","688235","LU0348767384.USD","02600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637399348","title":"智谱、MiniMax，有望加入恒生科技指数","url":"https://stock-news.laohu8.com/highlight/detail?id=2637399348","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637399348?lang=zh_cn&edition=full","pubTime":"2026-05-22 13:38","pubTimestamp":1779428280,"startTime":"0","endTime":"0","summary":"　　恒生指数公司将于今日收市后公布季度检讨结果。　　市场焦点集中在智谱、MiniMax这两只AI概念股，有望被纳入恒生科技指数及综合指数。　　根据市场分析，智谱、MiniMax因近期市值大幅上升，已成为纳入恒生科技指数的最有力候选。　　至于摩根士丹利此前预期，智谱、及MiniMax将于6月纳入恒生科技指数，合计权重约5%至7%，或带动12.5亿至17.5亿美元的被动资金流入，而纳入港股通可能会在6个月内将内地持股比例提升至自由流通股的9%至20%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-05-22/doc-inhytyys6180072.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1117","BK1500","03417","LU0823426308.USD","03067","01818","LU0348825331.USD","HSTECH","LU0417516902.SGD","BK1574","LU0348767384.USD","LU1961090484.USD","LU0348783233.USD","LU0417516571.SGD","LU0650527681.SGD","MHImain","LU2476274308.USD","00100","LU2488822045.USD","07500","LU0708994859.HKD","02423","BK1544","LU0348827113.USD","BK1583","IE00BPRC5H50.USD","LU1770034418.SGD","BK1097","IE00B5MMRT66.SGD","LU1969619763.USD","LU2279701549.SGD","LU1267930573.SGD","06160","03423","ONC","LU1303224171.USD","LU0348735423.USD","BK1588","03115","HHImain","LU0588546209.SGD","09926","03037","LU0823426480.USD","IE0034224299.USD","BK1198","LU2476274720.SGD","LU0634319403.HKD","03088","LU0348784397.USD","09987","IE00B543WZ88.USD","LU0307460666.USD","BK1161","688235","LU0228659784.USD","02837","MCHmain","LU0417516738.SGD","82800","09115","LU0128525929.USD","LU2328871848.SGD","09088","LU1719994722.HKD","02513","07300","83115","07200","BK1592","LU0029864427.USD","LU1720050803.USD","LU2399975544.HKD","03033","03419","HSI","513600","LU0594300419.USD","07226","BEKE","LU2778985437.USD","YUMC","07552","BK1233","LU1251922891.USD","LU0310800379.SGD","LU0561508036.HKD","03032","LU0348766576.USD","02800","09067","LU1794554557.SGD","LU0540923850.HKD","02833"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166008670","title":"异动解读 | 依沃西单抗全球三期中期未达终点，康方生物盘中大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166008670","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166008670?lang=zh_cn&edition=full","pubTime":"2026-05-22 09:58","pubTimestamp":1779415121,"startTime":"0","endTime":"0","summary":"康方生物今日盘中大跌5.08%，引起了市场的广泛关注。消息面上，此次下跌主要源于市场对其核心产品依沃西单抗全球关键三期HARMONi-3研究中期分析不及预期的持续消化。海外合作方Summit此前披露的研究中期结果显示，针对转移性非小细胞肺癌一线治疗的鳞状细胞癌队列，无进展生存期未达到预设的统计学显著性标准，这引发了市场对中国人群优异临床数据能否在全球范围复刻的担忧。尽管公司此前受ASCO摘要解禁及卡度尼利单抗新适应症获批临床等利好推动出现反弹，但短期估值修复动能仍显不足。公司股价已自前期高点累计回调超过25%，此次盘中表现显著弱于当日多数表现平稳的生物科技板块个股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144148892","title":"异动解读｜康方生物盘中下跌3.75%，依沃西单抗全球三期中期未达终点持续压制估值","url":"https://stock-news.laohu8.com/highlight/detail?id=1144148892","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144148892?lang=zh_cn&edition=full","pubTime":"2026-05-22 09:50","pubTimestamp":1779414607,"startTime":"0","endTime":"0","summary":"5月22日，康方生物盘中下跌3.75%，报115.5港元/股，成交额1.15亿港元。市场仍在持续消化其核心产品依沃西单抗全球关键三期HARMONi-3研究中期分析不及预期的影响。同日生物科技板块多数个股表现平稳，科伦博泰生物涨4.1%、三生制药涨1.42%，康方生物跌幅显著领先板块。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637804980","title":"【券商聚焦】中邮证券首予康方生物(09926)“买入”评级 指其商业化成绩显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2637804980","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637804980?lang=zh_cn&edition=full","pubTime":"2026-05-21 13:52","pubTimestamp":1779342721,"startTime":"0","endTime":"0","summary":"该行首次覆盖，给予“买入”评级。2025年公司全年收入30.6亿元，其中商业销售收入30.3亿元；净利润-11.4亿元，业绩符合预期。25年为公司医保元年，截至年底5款自主商业化创新药的12项适应症均已纳入医保，带动商业化收入快速增长。中邮证券预计公司26/27/28年收入分别为45.4/65.6/98.0亿元，同比增长48.5%/44.6%/49.4%；归母净利润为-5.2/-1.1/10.2亿元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/YjI3NDA0ZDhiMGQ3ZDhlYjY1NzQ2OTEyNjkyMTk4MTc4.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YjI3NDA0ZDhiMGQ3ZDhlYjY1NzQ2OTEyNjkyMTk4MTc4.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981925","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637803601","title":"港股异动 | 康方生物(09926)早盘涨超7% 卡度尼利单抗针对结肠癌适应症获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2637803601","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637803601?lang=zh_cn&edition=full","pubTime":"2026-05-21 10:44","pubTimestamp":1779331485,"startTime":"0","endTime":"0","summary":"消息面上，据CDE官网显示，康方生物按注册分类2.2类申报的卡度尼利单抗注射液临床试验申请获默示许可。据悉，卡度尼利单抗为全球首创PD-1/CTLA-4双特异性肿瘤免疫治疗药物。2022年6月，卡度尼利单抗首次获批上市，用于既往接受含铂化疗治疗失败的复发或转移性宫颈癌患者的治疗，填补了中国晚期宫颈癌免疫治疗的空白。截至目前，卡度尼利单抗静脉注射剂型已在国内获批三项适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348783233.USD","LU0348767384.USD","09926","LU0348825331.USD","LU0348735423.USD","LU0540923850.HKD","LU0417516571.SGD","LU0417516902.SGD","IE00B543WZ88.USD","LU0348766576.USD","BK4585","LU0634319403.HKD","LU1961090484.USD","BK4588","BK1161","IE00BPRC5H50.USD","LU0348827113.USD","LU1794554557.SGD","BK1574","LU2399975544.HKD","LU2488822045.USD","IE00B5MMRT66.SGD","LU2476274720.SGD","LU2778985437.USD","LU0417516738.SGD","LU2476274308.USD","VXUS","LU1720050803.USD","LU0348784397.USD","LU0561508036.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637035298","title":"康方生物(09926)涨逾6% 卡度尼利单抗注射液临床试验申请获默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2637035298","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637035298?lang=zh_cn&edition=full","pubTime":"2026-05-21 10:39","pubTimestamp":1779331159,"startTime":"0","endTime":"0","summary":"金吾财讯 | 康方生物 盘中涨逾6%，截至发稿，最新报122.20港元，涨幅6.26%，成交额6.56亿港元。消息面上，中国国家药品审评中心官网新近显示，康方药业有限公司按注册分类2.2类申报的卡度尼利单抗注射液临床试验申请获默示许可。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MGY1NDA5NTM4NDQ4Mw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGY1NDA5NTM4NDQ4Mw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981935","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1961090484.USD","LU0348825331.USD","LU0348827113.USD","LU0634319403.HKD","LU0417516571.SGD","LU2488822045.USD","09926","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU1794554557.SGD","BK1161","LU0348735423.USD","LU2399975544.HKD","LU0348784397.USD","LU1720050803.USD","LU0348766576.USD","LU2778985437.USD","BK1574","IE00BPRC5H50.USD","LU0540923850.HKD","LU0348767384.USD","LU2476274720.SGD","LU0348783233.USD","LU0417516738.SGD","LU2476274308.USD","LU0417516902.SGD","LU0561508036.HKD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1177207103","title":"异动解读 | 康方生物盘中大涨6.61%，ASCO摘要解禁在即叠加生物科技板块集体走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1177207103","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177207103?lang=zh_cn&edition=full","pubTime":"2026-05-21 09:49","pubTimestamp":1779328195,"startTime":"0","endTime":"0","summary":"康方生物今日盘中大涨6.61%，引起了市场的广泛关注。消息面上，美国临床肿瘤学会（ASCO）官网将于今日解除大部分常规摘要的禁运，届时康方生物旗下依沃西单抗和卡度尼利单抗的多项壁报展示细节将全面曝光，涉及头颈部鳞癌、转移性结直肠癌等新适应症拓展数据。此外，依沃西单抗已入选ASCO全体大会口头报告，市场对即将到来的重要学术窗口期寄予厚望。此前，受HARMONi-3全球三期中期分析未达终点影响，公司股价自4月高点已累计回调超20%，当前市场估值修复情绪明显升温。同日，生物科技板块整体表现强劲，板块共振效应也为股价上涨提供了支撑。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126385507","title":"异动解读｜康方生物盘中上涨3.22%，ASCO摘要解禁在即叠加生物科技板块集体走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1126385507","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126385507?lang=zh_cn&edition=full","pubTime":"2026-05-21 09:45","pubTimestamp":1779327946,"startTime":"0","endTime":"0","summary":"5月21日，康方生物盘中上涨3.22%，报122.3港元/股，成交额3.59亿港元。消息面上，ASCO官网将于今日解除大部分常规摘要的embargo，届时康方生物旗下依沃西单抗和卡度尼利单抗的多项壁报展示细节将全面曝光，涉及头颈部鳞癌、转移性结直肠癌等新适应症拓展数据。此外，依沃西单抗已入选ASCO全体大会口头报告，市场对即将到来的学术窗口期寄予期待。同日生物科技板块集体走强，科伦博泰生物涨5.22%、荣昌生物涨5.13%、信达生物涨3.97%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636030884","title":"【券商聚焦】招银国际：AI有望改变创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2636030884","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636030884?lang=zh_cn&edition=full","pubTime":"2026-05-19 13:13","pubTimestamp":1779167581,"startTime":"0","endTime":"0","summary":"当前，监管框架持续完善，传统药企与AI原生公司加速合作，AI制药正处于从研发提效工具迈向创新药研发范式重构的转折期。AI重构药物研发全链条，早期效率红利已率先显现。传统创新药研发长期受困于高成本、长周期和低成功率，AI技术正在改变靶点发现、分子筛选与优化等关键环节的研发范式。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981743","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B031HY20.USD","BK1161","LU1152091754.HKD","01177","02142","06160","LU0348767384.USD","159992","01877","LU0417516738.SGD","LU0456846285.SGD","LU0326950275.SGD","02616","LU0634319403.HKD","LU0561508036.HKD","02269","LU0140636845.USD","IE00BPRC5H50.USD","AGIX","LU1303224171.USD","BK1588","LU1960683339.HKD","AIPO","09926","LU0456827905.SGD","SG9999002562.SGD","LU0572944931.SGD","LU0315179316.USD","LU0348827113.USD","LU1880383366.USD","LU0516422952.EUR","LU0856984785.SGD","LU0067412154.USD","LU1152091168.USD","BK1583","LU1719994722.HKD","ARTY","01093","01801","06185","LU2097828631.EUR","06978","BK1589","LU0072913022.USD","LU1226287792.SGD","LU1993786604.SGD","LU1226288170.HKD","CHAT","09995","09688"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1198321368","title":"异动解读 | 依沃西单抗全球三期中期未达终点，康方生物盘中大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1198321368","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198321368?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:57","pubTimestamp":1779073043,"startTime":"0","endTime":"0","summary":"康方生物今日盘中股价大跌5.07%，引发市场关注。消息面上，此次下跌主要与市场持续消化其核心产品依沃西单抗全球关键三期HARMONi-3研究的中期分析结果有关。根据此前海外合作方Summit披露的数据，该研究针对转移性非小细胞肺癌一线治疗的鳞状细胞癌队列，其无进展生存期（PFS）未能达到预设的统计学显著性标准。这一结果引发了市场对于该药物在中国人群的优异临床数据能否在全球范围内成功复刻的担忧，从而持续压制公司估值。受此消息影响，公司股价自前期高点已出现显著回调，同期生物科技板块也整体承压。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636048086","title":"创新药概念走软 药明合联(02268)领跌5.57% 机构成仍看好以创新为主医药科技主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2636048086","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636048086?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:09","pubTimestamp":1779070152,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念整体走软，截至发稿，药明合联 跌5.57%，亚盛医药-B跌5.50%，四环医药跌4.55%，康方生物跌4.49%，歌礼制药-B跌4.36%，同源康医药-B跌4.31%，康诺亚-B跌4.24%，荣昌生物跌4.14%。展望2026年，该机构继续看好以创新为主的医药科技主线，重点关注创新药、脑机接口、AI医疗、手术机器人等，同时建议布局2026年行业有望迎来反转的老龄化及院外消费，关注估值较低的麻药、血制品、中药等。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981521","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0540923850.HKD","BK1161","01672","LU1969619763.USD","LU0348766576.USD","LU0348767384.USD","LU1961090484.USD","06855","159992","LU2328871848.SGD","LU0417516738.SGD","LU0348783233.USD","LU0417516571.SGD","IE00B5MMRT66.SGD","LU2476274308.USD","LU0634319403.HKD","LU2488822045.USD","SG9999014674.SGD","BK1141","02162","BK1593","09939","159938","LU0348735423.USD","LU0561508036.HKD","IE00BPRC5H50.USD","LU2778985437.USD","LU2399975544.HKD","09926","BK1587","IE00B543WZ88.USD","LU0348827113.USD","LU2476274720.SGD","02268","BK1574","BK1600","LU0348784397.USD","BK1515","00460","02410","BK1583","LU1720050803.USD","BK1191","06978","LU1794554557.SGD","LU0348825331.USD","LU0417516902.SGD","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636483820","title":"【券商聚焦】中信建投：创新药迎盈利兑现期 国内商业化与海外授权双轮驱动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2636483820","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636483820?lang=zh_cn&edition=full","pubTime":"2026-05-18 09:32","pubTimestamp":1779067963,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业触底回暖，创新药迎来盈利兑现期，国内商业化与海外授权双轮驱动业绩增长，多家企业扭亏。26Q1对外授权总额超600亿美元，ADC、双抗等前沿赛道交易持续火热。2026年ASCO年会94项中国研究中选口头报告，依沃西单抗登上全体大会，标志着中国创新药全球学术影响力迈上新台阶。国内支付端医保谈判与商保目录合力支持真创新。建议关注创新药国际化、边际改善等结构性机会。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981512","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1688375341.USD","IE00B5MMRT66.SGD","06160","LU0348827113.USD","02142","LU1226287875.USD","01801","LU0516422952.EUR","159992","IE00BZ08YT58.USD","LU1152091754.HKD","LU0417516738.SGD","01093","601066","09995","LU2097828557.USD","09926","02269","LU1242518857.USD","LU2097828474.EUR","LU0039217434.USD","LU1969619763.USD","SG9999002562.SGD","LU0516423174.USD","LU1242518931.SGD","LU0979878070.USD","LU1303224171.USD","02616","IE00BZ08YS42.EUR","01177","06978","IE00B543WZ88.USD","09688","LU0456827905.SGD","LU0561508036.HKD","IE00B0JY6N72.USD","BK1161","LU2399975544.HKD","01877","LU0326950275.SGD","IE00BZ08YR35.GBP","BK1141","BK1574","BK1588","LU0588546209.SGD","LU1152091168.USD","LU1993786604.SGD","06185","LU0359202008.SGD","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107515849","title":"Ligufalimab（抗CD47）联合疗法一线治疗AML的随机双盲试验II期数据于EHA 2026公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1107515849","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107515849?lang=zh_cn&edition=full","pubTime":"2026-05-15 15:45","pubTimestamp":1778831114,"startTime":"0","endTime":"0","summary":"一项关于Ligufalimab（抗CD47抗体）联合疗法用于一线治疗急性髓系白血病（AML）的随机双盲试验，其II期临床数据已在2026年欧洲血液学协会（EHA）大会上正式发布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1961090484.USD","LU0348825331.USD","LU0348827113.USD","LU0634319403.HKD","LU0417516571.SGD","LU2488822045.USD","09926","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU1794554557.SGD","BK1161","LU0348735423.USD","LU2399975544.HKD","LU0348784397.USD","LU1720050803.USD","LU0348766576.USD","LU2778985437.USD","BK1574","IE00BPRC5H50.USD","LU0540923850.HKD","LU0348767384.USD","LU2476274720.SGD","LU0348783233.USD","LU0417516738.SGD","LU2476274308.USD","LU0417516902.SGD","LU0561508036.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633687104","title":"【券商聚焦】中国银河：医药行业进入复苏周期 CXO板块景气度较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2633687104","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633687104?lang=zh_cn&edition=full","pubTime":"2026-05-08 09:00","pubTimestamp":1778202049,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国银河证券表示，2025年医药行业上市公司营业收入增长0.4%，归母净利润增长3.9%，扣非净利润下降4.1%，2026年一季度营业收入增长1.1%，归母净利润下降3.2%，扣非净利润增长2.0%。2025全年医药行业收入端小幅微增，主要系医保控费趋严，仿制药、耗材等集采常态化开展导致行业承压。2026年一季度创新药产业链高景气度延续，收入增幅扩大、非经常性损益占比下降，行业整体经营盈利能力提升，进入复苏上行周期。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980878","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588546209.SGD","06881","BK1161","BK1585","HK0000165453.HKD","LU0348767384.USD","LU2328871848.SGD","LU2476274720.SGD","03933","LU0417516902.SGD","LU2778985437.USD","02367","BK1583","LU0348766576.USD","02228","BK1593","BK1141","CXO","LU0640798160.USD","LU1719994722.HKD","BK1500","BK1588","02196","LU0348783233.USD","LU0561508036.HKD","06821","LU1303224171.USD","LU0307460666.USD","BK0276","01789","LU1251922891.USD","LU1794554557.SGD","02268","01530","BK1207","IE00BPRC5H50.USD","LU1961090484.USD","09688","LU0348735423.USD","06160","01099","LU0417516571.SGD","LU0417516738.SGD","LU0634319403.HKD","BK1197","09926","BK0188","601881","LU2488822045.USD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103227376","title":"康方生物4月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1103227376","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103227376?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:11","pubTimestamp":1778055085,"startTime":"0","endTime":"0","summary":"康方生物科技（开曼）有限公司于2026年5月6日公布截至2026年4月30日的股份变动月报表。报告显示，公司法定股本维持在5,000,000,000股普通股不变，每股面值USD 0.00001，总计USD 50,000。截至报告期末，公司已发行及流通在外普通股数量为921,143,176股，与上月底一致，库藏股数量为0股。据公布信息，截至2026年4月30日，公司满意香港联交所最低公众持股量要求，股本结构保持稳定。据月报显示，本次公告由公司董事夏瑜签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8d4c202617d87be1d9fe31f833a300a8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145664835","title":"异动解读 | 市场重新评估临床试验影响，康方生物盘中大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145664835","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145664835?lang=zh_cn&edition=full","pubTime":"2026-05-06 10:37","pubTimestamp":1778035037,"startTime":"0","endTime":"0","summary":"康方生物今日盘中大涨5.01%，引起了市场的广泛关注。消息面上，此次上涨主要源于市场对前期超跌的重新评估。此外，华福证券维持对康方生物的“买入”评级，并通过DCF模型测算其合理股价为206港元，指出当前股价仍存在较大的折价空间。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":-0.1474},{"period":"3month","weight":0.0645},{"period":"6month","weight":-0.1067},{"period":"1year","weight":0.3784},{"period":"ytd","weight":-0.0071}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0146},{"period":"3month","weight":-0.0436},{"period":"6month","weight":-0.0134},{"period":"1year","weight":0.0995},{"period":"ytd","weight":-0.0012}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康方生物科技（开曼）有限公司是一家致力于研究、开发、生产及商业化让全球病人可负担的抗体药的投资控股公司。该公司在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域。该公司的产品主要包括有用于肿瘤领域的开坦尼（卡度尼利，PD-1/CTLA-4）、依达方（依沃西，PD-1/VEGF）、莱法利（AK117，CD47）、普络西（AK109，VEGFR-2）、安尼可（派安普利，PD-1）、科泰莱（塔戈利单抗，PD-L1）和用于代谢及自免领域的伊喜宁（伊努西单抗，PCSK9）、爱达罗（依若奇单抗，IL-12/IL-23）、古莫奇单抗（AK111，IL-17）。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019031},{"month":3,"riseRate":0.5,"avgChangeRate":0.006875},{"month":4,"riseRate":0.833333,"avgChangeRate":0.041517},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.027512},{"month":6,"riseRate":0.666667,"avgChangeRate":0.133235},{"month":7,"riseRate":0.5,"avgChangeRate":0.087867},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":9,"riseRate":0.5,"avgChangeRate":0.036209},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"康方生物","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康方生物,09926,康方生物股票,康方生物股票老虎,康方生物股票老虎国际,康方生物行情,康方生物股票行情,康方生物股价,康方生物股市,康方生物股票价格,康方生物股票交易,康方生物股票购买,康方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}